Cellular Deoxyribonucleic acid (DNA) (DNA)

Cellular Deoxyribonucleic acid (DNA) is the fundamental molecule carrying genetic instructions for the development, functioning, and reproduction of all known organisms. In the context of pharmacology, it serves as the primary therapeutic target for alkylating agents such as cyclophosphamide (StatPearls, NBK553087). Cyclophosphamide itself is an inactive prodrug that undergoes metabolic activation in the liver, primarily via CYP2B6, to form phosphoramide mustard. This active metabolite reacts with DNA to create covalent adducts and cross-links (PubChem, CID 2907). These structural modifications, particularly at the N7 position of guanine, prevent the DNA strands from separating, thereby inhibiting essential processes like replication and transcription (DrugBank, DB00551). This mechanism is particularly effective against rapidly dividing cells, making DNA alkylation a key strategy in treating various cancers, including lymphomas and leukemias. Additionally, it is used to manage severe autoimmune conditions through potent immunosuppression. The resulting DNA damage, if unrepaired, triggers programmed cell death or apoptosis.

Other names

Deoxyribonucleic acidGenomic DNANuclear DNADNA

Cyclophosphamide is a nitrogen mustard prodrug that requires hepatic activation by cytochrome P450 enzymes (notably CYP2B6 and CYP3A4) to form 4-hydroxycyclophosphamide, which exists in equilibrium with aldophosphamide. Aldophosphamide then spontaneously decomposes into the active alkylating agent, phosphoramide mustard, and the toxic byproduct acrolein (StatPearls, NBK553087). Phosphoramide mustard forms covalent bonds with DNA, specifically at the N7 position of guanine residues, leading to the formation of interstrand and intrastrand cross-links (PubChem, CID 2907). These cross-links prevent DNA strand separation, stalling DNA polymerase and inducing double-strand breaks, which ultimately triggers p53-mediated apoptosis in proliferating cells (DrugBank, DB00551).